formulations

A tailored formulation with precise surfactant and stabilizer ratios stabilizes TCR-scFv bispecific proteins, addressing their instability issues and ensuring long-term stability and activity.

JP2024167394AInactive Publication Date: 2024-12-03IMMUNOCORE LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024152268
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-10
Filing Date
2024-09-04
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The formulation of bispecific proteins comprising soluble T cell receptor (TCR) and scFv is challenging due to their instability, particularly at low concentrations and high temperatures, leading to aggregation and loss of activity, which complicates storage and administration.

Method used

A pharmaceutical formulation with a specific weight-to-weight ratio of surfactant to protein (0.75:1 to 1.5:1) and a stabilizer-to-bulking agent ratio greater than 1:1, using excipients like polysorbate 20, trehalose, and mannitol, maintains protein stability and prevents aggregation.

Benefits of technology

The formulation ensures stability of TCR-scFv bispecific proteins during long-term storage at 2-8°C and high temperatures, maintaining biological activity and preventing physical and chemical degradation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167394000001_ABST
    Figure 2024167394000001_ABST
Patent Text Reader

Abstract

To provide a formulation of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV that maintains protein stability at low protein concentrations and during long-term storage at relatively high temperatures.SOLUTION: The present invention relates to a pharmaceutical formulation comprising (i) a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV; and (ii) a surfactant. The w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1. The formulation may further comprise a bulking agent and / or a stabiliser. A further pharmaceutical formulation comprises (i) a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV; (ii) a bulking agent; and (iii) a stabiliser. The w / w ratio of stabiliser to bulking agent may be greater than 1:1.SELECTED DRAWING: Figure 1-1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a formulation. Specifically, the present invention relates to a soluble T cell receptor (TCR) and scFv The present invention relates to a pharmaceutical formulation of a bispecific protein comprising: [Background technology]

[0002] Advances in biotechnology have made it possible to engineer proteins for pharmaceutical use. Proteins are larger and more complex than traditional organic and inorganic drugs (e.g., complex Since these proteins have multiple functional groups in addition to their three-dimensional structure, formulation of such proteins is problematic. For a protein to remain biologically active, a formulation must preserve intact the steric integrity of at least the core sequence of amino acids of the protein while at the same time protecting the protein's multiple functional groups from degradation. Protein degradation pathways include chemical instability (e.g., the destruction of the protein by bond formation or cleavage resulting in new chemical entities). Any process involving alteration of the quality or physical instability (e.g., alteration of the higher-order structure of a protein) Chemical instability can involve deamidation, racemization, hydrolysis, acid Physical instability can be the result of, for example, denaturation, aggregation, precipitation or adsorption. The three most common protein degradation pathways are protein aggregation, deamidation and oxidation (Cleland et al., Critical Reviews in Therapeutic Drug Carrier Systems 10(4): 307-377 (1993)).

[0003] Antibodies (including fragments and variants) are one class of therapeutic proteins for which successful pharmaceutical formulations have been described (Wang et al., J Pharm Sci. 2007 Jan;96(1):1-26.). However, bispecific proteins comprising a soluble T cell receptor (TCR) and an scFV The art of stable pharmaceutical formulations of antibodies is extremely limited. Due to the known complexities of protein formulations and the many differences between TCR bispecific proteins and antibodies, formulation of antibodies is difficult. We expect that the techniques developed for the synthesis of bispecific TCR proteins will be applicable to these bispecific TCR proteins. For example, in antibody formulations, high protein concentrations (i.e., 1 mg / ml or higher) are not possible. This is desirable to minimize the volume of pharmaceutical agent administered to a patient while maintaining the required therapeutic effect. Since the TCR-scFv bispecific proteins are designed to be particularly potent at low protein concentrations, formulations with low protein concentrations (i.e., 1 mg / ml or less) are desirable. This is particularly problematic because low levels of agglomeration or brief contact with the vial surface ( Even a small amount of protein (i.e., absorption loss) can result in a significant loss of protein activity. do.

[0004] Furthermore, unlike antibodies, TCRs are known to be inherently unstable in solution. This means that the temperature is relatively high (e.g., -30°C or higher, e.g., 2 to 8°C) and / or for a long period of time. This means that maintaining protein stability during storage is not easy. Stability of therapeutic proteins at relatively high temperatures and during long-term storage is a desirable feature, allowing for convenient and low-cost transportation and storage to / at clinical facilities. Finally, Glycosylation is an important consideration in antibody formulations because changes in glycosylation can affect the rate of protein degradation. TCR-scFv bispecific proteins are generally not glycosylated, as they are produced in E. coli. Summary of the Invention [Problem to be solved by the invention]

[0005] A need exists to provide pharmaceutical formulations for TCR-scFv bispecific proteins that are particularly desirable for maintaining protein stability at low protein concentrations and during extended storage periods at relatively high temperatures. [Means for solving the problem]

[0006] In a first aspect, the present invention provides a A therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV. Quality; and Surfactants wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1.

[0007] In a second aspect, the present invention provides a method for producing a semiconductor device comprising the steps of: A therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV. Quality; Bulking agents; and Stabilizers wherein the w / w ratio of stabilizer to bulking agent is greater than 1:1. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. [Diagram 2] FIG. 2 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml of an alternative TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. [Diagram 3]FIG. 3 provides the results of a light obscuration analysis for formulations comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.06%, 0.04%, 0.02%, 0.01% or 0.005% Tween 20. [Figure 4] FIG. 4 provides the results of a Design of Experiments (DoE) analysis for formulations comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07% or 0.08% Tween 20. [Diagram 5] FIG. 5 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.5 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 7.5, 120 mM NaCl and 0.05% Tween 20. [Figure 6] FIG. 6 provides the results of a turbidity analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% mannitol and 0.02% Tween in the presence or absence of 1% sucrose. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] In a first aspect, the present invention provides a method for producing a composition comprising: A therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV. Quality; and Surfactants wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1.

[0010] We have found that w / w ratios of surfactant to protein in the range of 0.75:1 to 1.5:1 result in stable formulations. Surfactants are commonly used excipients in protein formulations to prevent both protein aggregation and surface absorption. It has been shown in the art that a wide range of surfactant concentrations are adequate to prevent aggregation (0.02-2.0 mg / mL or 0.002-0.2%) and that the higher the concentration, the better the prevention of precipitation (Wang, Eur. J Pharm Biopharm. 2017 May;114: 263-277). Furthermore, in known protein formulations, In common practice, the weight of protein is in substantial excess relative to the weight of surfactant; for example, in formulations of the marketed therapeutic antibodies trastuzumab (Heceptin®) and bevacizumab (Avastin®), the antibody is present in greater than 50-fold excess relative to the surfactant. found that in TCR-scFv bispecific protein formulations, increasing or decreasing the w / w ratio of detergent to protein outside the narrow range of 0.75:1 to 1.5:1 unexpectedly resulted in a substantial loss of protein stability. Without being bound by theory, the inventors hypothesize that the low protein concentration in the formulation as a result of the high potency of the drug means that the protein is more sensitive to small changes in detergent concentration.

[0011] The w / w ratio of detergent to protein may be in the range of 0.8:1 to 1.2:1, 0.9:1 to 1.1:1 or 0.95:1 to 1.05:1. The ratio may be 0.75:1, 0.8:1, 0.85:1, 0.9:1, 0.95:1, 1:1, 1.05:1, 1.1:1, 1.15:1, 1.2:1. The preferred ratio is 1:1. The formulations of the present invention may comprise one or more pharma- ceutically acceptable surfactants. Examples of pharma- ceutically acceptable surfactants include polysorbates (e.g., polysorbate 20). , 40, 60 or 80); poloxamer (e.g. poloxamer 188); triton; sodium octyl glucoside; lauryl-, myristyl-, linoleyl- or stearyl-sulfobetamine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl- Styryl- or cetyl-betamin; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl- or isostearamidopropyl Pyr-betamine (e.g. lauroamidopropyl); myristamidopropyl-, palmidopropyl- or isostearamidopropyl-dimethylamine; sodium methyl cocoyl taurate oleyl methyl taurate disodium, polyethyl glycol, polypropyl glycol Examples of surfactants include glycerol and copolymers of ethylene and propylene glycol. Preferably, the surfactant in the formulation of the present invention is a polysorbate, such as polysorbate 20 (trade name Tween® 20) or polysorbate 80 (trade name Tween® 80). More preferably, the surfactant is polysorbate 20 (Tween® 20). The surfactant may be present at a w / v concentration of 0.1% or less, for example 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%. The surfactant concentration may be 0.02%. The surfactant concentration may be 0.05%. Preferably, the surfactant is polysorbate 20 and is present at a concentration of 0.02%. The formulation of the first aspect may further comprise a bulking agent and / or a stabilising agent. Preferably the ratio of stabilising agent to bulking agent is greater than 1:1.

[0012] In a second aspect, the present invention provides a method for producing a composition comprising: A therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV. Quality; Bulking agents; and Stabilizers wherein the w / w ratio of stabilizer to bulking agent is greater than 1:1.

[0013] The inventors have found that using a bulking agent and a stabilizing agent in a w / w ratio of stabilizer to bulking agent greater than 1:1 results in a stable formulation that is easily lyophilized. Mixtures comprising a disaccharide stabilizer (e.g., trehalose or sucrose) and a bulking agent (e.g., mannitol) are known to be suitable excipients for lyophilized protein formulations (Johnson, J Pharm Sci. 2002 Apr;91(4):914-22). Mannitol readily forms a crystalline structure, facilitating the production of a stable cake that does not collapse during drying. However, in the crystalline state, mannitol cannot react with proteins and may aggregate. Sucrose (amorphous Achieving a good compromise between cake stability and agglomeration prevention is possible by adding a glycerol-containing glycerol (which forms a phase). To provide an adequate balance, a mannitol to sucrose weight ratio of at least 3:1 is recommended. is proposed to be necessary; lower ratios have been shown to inhibit crystallization of mannitol (Jena et al., Pharm Res. 2016 Jun;33(6):1413-25; Johnson et al., J Pharm Sci. 2002 Apr;91(4):914-22). Contrary to teachings in the art, the inventors have found that a ratio of bulking agent (e.g., mannitol) to stabilizing agent (e.g., sucrose / trehalose) of less than 1:1 (preferably 1:5) results in a stable cake in which clumping is minimized. The inventors hypothesized that crystalline mannitol, when present in excess, may cause excessive distortion in the structure of the TCR-scFv bispecific protein in the lyophilized state, leading to subsequent unfolding, denaturation and aggregation.

[0014] The w / w ratio of stabilizer to bulking agent is preferably 3:1 to 5:1, more preferably 4:1 to 6:1. For example, the ratio can be 2:1 or 3:1 or 4:1 or 5:1 or 6:1. The ratio of the stabilizer to the bulking agent may preferably be about 5:1, for example 5.5:0.9-4.5:1. The ratio of the stabilizer to the bulking agent may more preferably be 5:1. The concentration of the stabilizer may be within the range of 4.5-5.5% (w / v), for example 5%. The concentration of the bulking agent used in the formulation may be within the range of 0.9-1.1% (w / v), for example 1%. Bulking agents are pharma- ceutically acceptable compounds that function to increase the bulk of the lyophilized cake (lyocake). Compounds that function as bulking agents are known in the art and include polyols (e.g., mannitol or sorbitol), carbohydrates, monosaccharides, polymers, or proteins. Preferably, the bulking agent is a polyol. More preferably, the bulking agent is mannitol. Preferably, the mannitol is present at a concentration of 1%.

[0015] Stabilizers act as lyoprotectants / cryoprotectants during freezing or lyophilization. and thus preventing aggregation and / or other chemical or physical instability. It is a pharma- ceutically acceptable compound. Compounds that function as stabilizers are known in the art. Examples of stabilizers include sugars, sugar-alcohols, and amino acids. Preferably, the stabilizing agent is a disaccharide. More preferably, the stabilizing agent is trehalose or sucrose. The stabilizing agent may be a mixture of trehalose and sucrose. Preferably, the stabilizing agent is trehalose, present at a concentration of 5%. In a preferred formulation of the invention, the stabilizing agent is trehalose and the bulking agent is mannitol. The w / w ratio of trehalose to mannitol is preferably 5:1.

[0016] The formulation of the present invention may further comprise a buffering agent. Pharmaceutically acceptable buffering agents are known in the art. Examples include phosphate, citrate, lysine, histidine, acetate, succinate and Tris buffers. Any of these may be used in the present invention. A preferred buffering agent is a phosphate-citrate buffer. The concentration of the buffering agent is about 20 mM. It may be up to about 50 mM, for example 20 mM, 30 mM, 40 mM or 50 mM. Preferably, the buffer concentration is 50 mM. Preferably, the formulation comprises 50 mM phosphate-citrate buffer. The optimum pH of a pharmaceutical formulation depends on the primary sequence of the protein and its concentration, as well as the identity and concentration of other excipients. In a preferred formulation of the present invention, the pH is in the range of about pH 6 to about pH 7, preferably 6.3 to 6.7. For example, the pH can be pH 6.0 or pH 6.1 or pH 6.2 or pH 6.3 or pH 6.4 or pH 6.5 or pH 6.6 or pH 6.7 or pH 6.8 or pH 6.9 or 7.0. pH 6.5 is preferred. pH 6.0 is also preferred.

[0017] The formulation may be an aqueous formulation. Preferably, the aqueous carrier is pharma- ceutically acceptable (e.g., The aqueous carrier is distilled water or sterile water. In some embodiments, the aqueous formulation may be frozen. Alternatively, the aqueous formulation may be lyophilized to produce a lyophilized formulation. Suitable protocols and methods for producing lyophilized pharmaceutical formulations from liquid formulations are known in the art. Methods for reconstituting lyophilized formulations prior to administration are known in the art. Briefly, lyophilization involves freezing the formulation and then sublimating ice from the frozen contents at a temperature appropriate for primary drying. Typically, primary drying is accomplished at moderate pressure (typically about 0.05 mBar). -0.5mBar) and a temperature range of about -30 to 25°C (however, the formulation is in the primary drying period) The formulation, the size and type of container holding the sample (e.g., glass vial), and the volume of liquid primarily affect the time required for drying, which can range from a few hours to several days. The secondary drying stage depends on the type and size of the container and the tank used. The secondary drying may be carried out at about 0-40° C., depending primarily on the type of protein. The time and pressure required for secondary drying will produce a suitable lyophilized cake and will depend, for example, on temperature and other parameters. Secondary drying time is influenced by the desired residual moisture level in the formulation and typically requires at least about 5 hours (e.g., 15-24 hours). The pressure may be the same as that used during the primary drying step. Lyophilization conditions may vary depending on the formulation and vial size.

[0018] The pharmaceutical formulations of the present invention are preferably stable. The term "stability" or "stable" as used herein refers to the stability of one or more biophysical and / or chemical properties of a bispecific protein. "Stable" refers to a formulation whose properties are essentially unchanged upon storage at 2-8°C for an extended period of time. By long term it is meant up to at least 2 years, more preferably up to at least 5 years or longer. Additional or alternative conditions may be used as indicators of the long term stability capability of a formulation at 2-8°C. For example, "stable" may mean that the protein is essentially unchanged after a specified number of freeze-thaw cycles, e.g., at least 5 or at least 10 freeze-thaw cycles; alternatively, "stable" may mean that the protein is essentially unchanged after shorter storage periods at higher temperatures, e.g., at least 1 month at a temperature of about 30°C.

[0019] The stability of a formulation may be evaluated by one or more biophysical or chemical properties, such as appearance (color and turbidity), time Protein concentration, pH, presence of subvisible particles, aggregation, denaturation and protein The activity of the antibody may be evaluated by testing the activity of the antibody, including but not limited to protein activity. Those skilled in the art are aware of the various analytical techniques that can be used to assess the stability of protein formulations. Examples include visual inspection, nephelometry, light obscuration, absorbance at 280 nm, capillary gel electrophoresis, and the like. CGE, anion exchange chromatography (AIEX), size exclusion chromatography These include, but are not limited to, column chromatography (SEC), and protein activity assays. For samples, further analytical techniques may include cake physical stability assessment and moisture content measurement (e.g., by Karl Fischer evaluation). Specific techniques are further provided in the Demonstration section. Preferably, the stability of the formulation is determined by assessing one or more, preferably all of the following properties: pH, appearance, protein concentration, presence of sub-visible particles, CGE, SEC, AIEX and protein activity.

[0020] The bispecific protein comprises a soluble TCR and an scFv antibody fragment, preferably The two are fused via a linker. The linker sequence is usually flexible in that it is made of amino acids that do not have bulky side chains that may limit its flexibility, such as glycine, alanine, and serine. The usable or optimal length of the linker sequence is easily determined. In many cases, the linker sequence is about 12 amino acids or less in length, such as 10 amino acids or less or 5-10 amino acids in length. The TCR consists of two disulfide-linked chains. Each chain (α and β) is generally considered to have two domains, a variable and a constant domain (referred to as TRAV / TRBV and TRAC / TRBC, respectively). The variable domain of each chain is located at the N-terminus. The soluble TCR comprises three complementarity determining regions (CDRs) embedded in a framework sequence. The CDRs comprise the recognition site for peptide-MHC binding. The soluble TCR does not include TRAV and TRBV. Soluble TCRs may be of any suitable class, preferably human. Soluble TCRs may contain mutations relative to a natural or wild-type (preferably human) TCR such that they have greater than physiological affinity for an antigen (examples of antigens include NY-ESO, MAGEA4 or PRAME). Soluble TCRs may be a heterodimeric αβ TCR polypeptide pair, in which the α and β polypeptides each have TCR variable and constant regions, but lack the TCR transmembrane and cytoplasmic regions. Residues identical in the constant regions of the TCR α and β polypeptides. There may be non-native disulfide bonds between the soluble TCRs. Soluble TCRs may recognize antigens presented on diseased cells (e.g., cancer cells) or cells infected with viruses or bacteria. The two chains of the soluble TCR can be produced as single chains (WO2004 / 033685) or as disulfide-linked dimers (WO03 / 020763). In one specific embodiment, the soluble TCR comprises an αβ heterodimer having the TRAV and TRBV regions and the extracellular α chain TRAC constant domain sequence and the extracellular β chain TRBC1 or TRBC2 constant domain sequence. The TRAC or TRBV sequence may be modified by truncation or substitution to eliminate the native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2. The TRAC or TRBV sequence may be modified by substitution of Thr 48 of TRAC and Ser 57 of TRBC1 or TRBC2 with cysteine ​​residues, even if the cysteine ​​forms a disulfide bond between the α and β constant domains of the TCR. The constant regions of the α and β polypeptides may be linked by a native disulfide bond between Cys4 of exon 2 of TRAC*01 and Cys2 of exon 2 of TRBC1 or TRBC2. Soluble TCRs are of the Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ or Vα-L-Vβ-Cβ type (where V α and Vβ are the TCR α and β variable regions, respectively, and Cα and Cβ are the TCR α and β variable regions, respectively. where L is a linker sequence).

[0021] The term "single-chain Fv" or "scFv" refers to an antibody fragment comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. The scFv may be derived from a human antibody or may be humanized. The scFv may be derived from an antibody that recognizes CD3. In one specific embodiment, the anti-CD3 scFv can be derived from the UCHT1 antibody (Shalaby et al., J. Exp Med. 1992 Jan 1;175(1):217-25, US5821337). scFv is a soluble TCR that is attached to the N- or C-terminus. It may be fused. It is preferred that the scFv is fused to the N-terminus of the soluble TCR (WO2010 / 133828). The TCR-scFv bispecific protein may be present at a concentration of 1 mg / ml or less, 0.5 mg / ml or less, preferably 0.3 mg / ml or less. The concentration of the TCR-scFv bispecific protein is 0.05 to 0.5 mg / ml or 0.1 It may be in the range of -0.3mg / ml, and may be 0.5, 0.4, 0.3, 0.2 or 0.1mg / ml. The preferred concentration is 0.2mg / ml.

[0022] Specific TCR-scFv bispecific proteins that may be included in the formulations of the invention include those disclosed in WO2011001152, WO2017 / 109496, WO2017 / 175006 and WO2018234319. Certain TCR-scFv bispecific proteins comprise an alpha chain of SEQ ID NO: 45 (wherein amino acids 1 to 109 are replaced with SEQ ID NO: 8, the amino acid at position 1 is A, and the C-terminus of the alpha chain is Based on the numbering, eight amino acids from F196 to S203 (inclusive) have been truncated; and and a β-chain of SEQ ID NO: 36 (wherein residues 259-370 correspond to SEQ ID NO: 27 and amino acids 1 and 2 correspond to SEQ ID NO: 27). The amino acids are A and I, respectively. The formulation may preferably have a pH of 6.5.

[0023] One specific formulation according to the invention comprises: TCR-scFv bispecific protein, which is an alpha chain of SEQ ID NO: 45 of WO2011001152, wherein amino acids 1 to 109 are substituted with SEQ ID NO: 8 of WO2011001152, where the amino acid at position 1 is A, and the C-terminus of the alpha chain is truncated by 8 amino acids from F196 to S203 (inclusive) based on the numbering of SEQ ID NO: 45) and a beta chain of SEQ ID NO: 36 of WO2011001152, where residues 259 to 370 correspond to SEQ ID NO: 27 of WO2011001152, where the amino acids at positions 1 and 2 are A and I, respectively, and is present at a concentration of 0.2 mg / ml. 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.02% w / v Polysorbate 20 and has a pH of 6.5.

[0024] In one alternative preferred embodiment, the formulation comprises: 0.5mg / ml TCR-scFv bispecific protein, such as those described in WO2017 / 109496; 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.05% w / v Polysorbate 20 and has a pH of 6.0.

[0025] In a further alternative preferred embodiment, the formulation comprises 0.2mg / ml TCR-scFv bispecific protein, such as those described in WO2017 / 175006; 50mM phosphate-citrate buffer, 5% trehalose, 1% mannitol, and 0.02% w / v Polysorbate 20 and has a pH of 6.0. Preferably, the bispecific protein in the formulation of the invention is non-glycosylated.

[0026] In a further aspect, the present invention also provides a method for producing a composition comprising the steps of: (i) a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV, and (ii) a surfactant; Here, a method for producing a pharmaceutical formulation is provided, wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:1. In a further aspect, the present invention also provides a method for producing a composition comprising the steps of: (i) formulating a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV, (ii) a bulking agent, and (iii) a stabilizing agent; Here, a method is provided for producing a pharmaceutical formulation, in which the ratio of stabilizer to bulking agent is greater than 1:1. do.

[0027] The invention also provides a formulation of the invention for use in medicine. The formulation may be for use in a method of treating a disease, including cancer, or an infectious disease. Cancer may be melanoma (cutaneous melanoma). The cancer may be cutaneous or uveal melanoma (also known as intraocular melanoma), lentigo maligna, superficial spreading melanoma, acral lentigo, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, amelanotic melanoma, soft-tissue melanoma, small cell melanoma with small nevus-like cells, and spitzoid melanoma, including, but not limited to, melanomas. Alternatively, the cancer may be breast cancer (including triple negative), ovarian cancer, endometrial cancer, esophageal cancer, lung cancer (NSCLC and SCLC), bladder cancer, colon cancer, stomach cancer, liver cancer, pancreatic cancer, prostate cancer, connective tissue cancer (i.e., sarcoma), or head and neck cancer; or the cancer may be leukemia or lymphoma.

[0028] In a preferred embodiment, the formulations may be administered by injection, for example, intravenous injection. The formulations may be administered by continuous infusion (e.g., over hours, days, or weeks) or intermittent infusion (e.g., once a week). The dose may be administered once, twice or three times, or less frequently. Alternatively, the formulation may be adapted for administration by any other suitable route, including intratumoral, subcutaneous, intramuscular, intrathecal, enteral (including oral or rectal), inhaled or intranasal.

[0029] In a further aspect, the present invention provides a method of treating a human subject comprising administering to the human subject a therapeutically effective amount of the pharmaceutical formulation disclosed herein. Preferred features of any one aspect of the invention apply mutatis mutandis to each other aspect of the invention. Prior art documents referred to herein are incorporated to the fullest extent permitted by law.

[0030] The invention will now be described in the following non-limiting Examples, with reference to the accompanying drawings in which: FIG. 1 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. FIG. 2 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.2 mg / ml of an alternative TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and 0.02% Tween 20. FIG. 3 shows the results of incubation with 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.06%, 0.04%, 0.02%, 0.01% or 0.005% 1 provides the results of a light-obscuration analysis for a formulation comprising Tween 20. FIG. 4 shows the results of a Design of Experiments (DoE) analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% trehalose, 1% mannitol and either 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07% or 0.08% Tween 20. to provide. FIG. 5 provides the results of SE-UPLC, AE-HPLC and CGE analysis for a formulation comprising 0.5 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 7.5, 120 mM NaCl and 0.05% Tween 20. FIG. 6 provides the results of a turbidity analysis for a formulation comprising 0.2 mg / ml TCR-scFv bispecific protein, 50 mM phosphate-citrate pH 6.5, 5% mannitol and 0.02% Tween in the presence or absence of 1% sucrose. EXAMPLES

[0031] Working Example Example 1 - Stable aqueous formulation for soluble TCR-scFv bispecific proteins A) A bispecific protein comprising a soluble TCR fused to an anti-CD3 scFv (see WO2011 / 001152). an alpha chain of SEQ ID NO: 45, where amino acids 1-109 are replaced with SEQ ID NO: 8 of WO2011001152, the amino acid at position 1 is A, and the C-terminus of the alpha chain is F196 based on the numbering of SEQ ID NO: 45 The β-chain of SEQ ID NO: 36 of WO2011 / 001152 (wherein residues 259-370 correspond to SEQ ID NO: 27 of WO2011 / 001152 and the amino acids at positions 1 and 2 are A and I, respectively) was prepared using known methods and analyzed by size exclusion chromatography. The protein was then buffer exchanged into formulation buffer using semi-permeable column chromatography (SEC). The protein was then diluted with formulation buffer to a final concentration of 0.20±0.02 mg / mL and bottle-exchanged in a laminar airflow (LAF) bench. was filled. The formulation buffer was 50 mM phosphate-citrate, 5% trehalose, 1% mannitol and 0.02 % Tween 20. The pH was 6.5.

[0032] Protein stability was monitored over a 24-month period at either <-60°C or +5°C. Stability at each temperature was assessed using capillary gel electrophoresis (CGE), anion exchange high performance liquid chromatography (AHPLC), and ELISA. Various methods, including size exclusion ultra-performance liquid chromatography (AE-HPLC) and size exclusion ultra-performance liquid chromatography (SE-UPLC), are available. The protein stability was evaluated using analytical methods such as those described in the literature. Further evaluation included visual inspection, measurement of protein content and pH, detection of subvisible particles by light obscuration method, and activity assays to confirm functionality. Protein stability was also demonstrated over 10 freeze-thaw cycles. SE-UPLC was used to detect the presence of multimers and other high molecular weight species. SE-UPLC was performed on a UPLC system using a 1.7 μm, 4.6×300 mm UPLC SE column with an isocratic mobile phase of 0.2 M phosphate pH 7.5 (0.2 ml / min). The method was run ...) after injection of an appropriate volume onto the column. The system involves the separation of protein components in a test sample on an SE column with detection by fluorescence. Figure 1A shows the results of the separation of protein components in a test sample on an SE column at +5°C over a period of 24 months at 8 time points. The purity assessment is shown. At 0 months, the purity was 99.2% and at 24 months, it was 99.3%. The minimum acceptance criteria was ≥ 95%.

[0033] Charge-based decomposition was detected using AE-HPLC, which was performed using a 2 × 250 mm weak AE column. The analysis was carried out on an HPLC system using a mobile phase of phosphate pH 8.2 (0.2 ml / min). The protein was eluted using a gradient of NaCl in phosphate (pH 8.2) buffer. involves the separation of protein components in a test sample on an AE column with detection by fluorescence in an HPLC system after injection of an appropriate volume onto the column. Figure 1B shows the evaluation of the charge state measured by AE-HPLC at 8 time points over a period of 24 months at +5°C. % Main Peak at Month 0 was +3.4% compared to the reference value and the reading at 24 months was -1.9%, demonstrating that the product was stable in this formulation (acceptance criteria: within ±15% of the reference). CGE was used to determine the presence of low molecular weight impurities and degradants (eg, fragments). The method was carried out using chips and standard CGE. In the chip method, the samples were diluted to 0.2 mg / mL. The final concentration was adjusted and heated at 70°C for 5 min. After cooling, the denatured samples were loaded onto the chip and separated by Bioanalyzer (Agilent technologies). Standard CGE was performed on a PA 800 plus instrument equipped with a diode array detector (Beckman Coulter) using reagents from the Proteolab SDS MW analysis kit and separation capillaries (57 cm × 50 μm ID, bare fused-silica). Samples were adjusted to 0.2 mg / mL before dilution in SDS sample buffer and incubated at 70°C for 5 min. The analysis was read at 220 nm and migration times and % corrected peak areas were recorded. Minimum acceptance criteria ≥ 95%.

[0034] FIG. 1C shows the evaluation of purity by CGE at 7 time points over a 24 month period at +5° C. The purity at T=24 months was 99.6% and at T=24 months was 99.7%, demonstrating that the product was stable in this formulation. Stability assessment after multiple freeze / thaw cycles was used as an additional indicator of long-term stability. The freeze-thaw cycle was performed by rapidly freezing the samples to <-60°C and then incubating them at room temperature (approximately 22°C). Stability was evaluated by SE-UPLC as described above. Results were consistent after 10 freeze-thaw cycles. The purity was 99.6% before the freeze-thaw cycle and 99.5% afterwards, indicating that the product was stable in this formulation. The visual analysis was performed according to the principles of the methods described in the Pharmacopoeias (European Pharmacopoeia 2.2.1, 2.2.2 and 2.9.20). A clear, colorless solution (essentially free of particles) was observed at 0 months and after 24 months at +5° C. In addition, no visible changes were detected after 10 freeze-thaw cycles.

[0035] Protein concentrations and pH were within ±0.02 mg / ml and ±0.2 pH units of the values ​​after 24 months. Evaluation of particles invisible to the naked eye using the laser light obscuration method showed that after 24 months, particles ≧25 μm were ≦600 / and ≥ 10 μm particles present at ≤ 6000 / vial (i.e., within the acceptance criteria). Turbidity measurements were within acceptable limits (<3 NTU (standard of opalescence I)). These data demonstrate that the formulation was stable over an extended storage period at temperatures between 2 and 8°C. The lyophilized preparation was prepared by freezing 0.6 ml samples in 2R glass vials and storing them at -45°C for 2 hours. The freeze-dried samples were prepared by holding for 10 min at -15°C / 0.07 mbar for 22 h, followed by primary drying at -15°C / 0.07 mbar for 22 h, then secondary drying at +40°C / 0.07 mbar for 23 h. The samples were then sealed in vials with rubber stoppers under vacuum. The freeze-dried samples were stored long term at +5°C. 0.6 ml of sterile water for injection was added to the vials. The samples were reconstituted by adding to the flask and mixing.

[0036] B) A second bispecific protein comprising an alternative soluble TCR (described in WO2017 / 175006) fused to an anti-CD3 scFv was prepared to a final concentration of 0.20±0.02 mg / mL. The formulation buffer was 20 mM It contained phosphate-citrate, 5% trehalose, 1% mannitol and 0.02% Tween 20. The pH was 6.0. Stability evaluation was performed over a 12 month period using the same method as in Part "A". The data of SE-UPLC, AE-HPLC and CGE are shown in Figures 2A-C, respectively. Purity by SE-UPLC was The charge state by AE-HPLC was 98.9% at 0 month and 99.3% at 12 months compared to the reference. The main peak was -12.2% in January and -19.5% in December (acceptance criteria: ±20% of the reference). %. Purity by CGE was 98.8% at 0 months and 98.3% at 12 months. In each case, extrapolation of the data indicates that stability can be predicted to be ≥ 24 months. Stability was also demonstrated by SE-UPLC after 10 freeze-thaw cycles. These data demonstrate that the formulation is stable during long-term storage at temperatures between 2-8°C.

[0037] Example 2 - Formulation Optimization A - Detergent to protein ratio The weight ratio of surfactant to protein was found to be an important factor in producing a stable formulation. Evidence for this is the presence of 2 μm or larger size fragments after five freeze-thaw cycles. The formulation buffer contained the TCR-scFv bispecific protein of Example 1A, 50 mM phosphate-citrate, 5% trehalose, and was determined from a laser light obscuration (LO) measurement that assessed the presence of particles subvisible to the naked eye. The assay contained 0.4 ml of ethanol, 1% mannitol and Tween 20 at one of five different concentrations. The pH was 6.5. The protein concentration was kept constant at 0.2 mg / ml. The assay was performed on a PAMAS SVSS-C or equivalent particle size determination device. A pre-work volume of 0.4 ml and a measurement volume of 0.1 ml were used. Samples were analyzed neat. Analyses were performed in triplicate. Particle counts were determined for particles ≧2 μm, ≧10 μm, and ≧25 μm.

[0038] FIG. 3 shows that the lowest number, and therefore the highest stability, for particle sizes ≧10 μm was obtained at a Tween-20 to protein ratio of 1. Further evidence that detergent to protein ratio is important comes from a design of experiments (DoE) study. In this experiment, the stability of the bispecific protein of Example 1A was tested under 32 different conditions at a fixed protein concentration of 0.2 mg / ml. Variables included surfactant concentration. In each case, the formulations were stored at +30°C ± 3°C for 1 month and stability was monitored for 5x freeze-thaw cycles at elevated temperatures. The effect of Tween 20 concentration (hence Tween 20 / protein w / w ratio between 1 and 4) was assessed by several analytical methods including SE-UPLC, AE-HPLC and CGE. In addition, the activity of the bispecific protein was evaluated using ELISA. The results are shown in Figure 4. Summarized.

[0039] B-Mannitol + Sucrose / Trehalose The inclusion of both mannitol and sucrose or trehalose was found to be an important factor in the formulation and necessary to provide a formulation that was easy to lyophilize. The bispecific protein of Example 1A was prepared in a formulation buffer containing 50 mM phosphate-citrate, 120 mM NaCl and 0.05% Tween 20 at a final protein concentration of 0.5 mg / ml. The pH was 7.5. The stability was evaluated using the same method as described in Example 1. Figures 5A-C show the stability of the The data shows SE-UPLC, AE-HPLC and CGE data over a 36 month period. The data shows that this formulation was not stable after 12 months. Subsequently, using DoE methodology, it was found that the addition of either 5% mannitol or 5% sucrose improved stability. The absence of NaCl was also preferred. However, the formulation containing 5% mannitol showed high levels of aggregation after 10 freeze-thaw cycles as determined by laser light obscuration (LO) method and turbidity (NTU) measurements. Turbidity was measured nephelometrically using a turbidimeter and calibration against known turbidity standards. FIG. 6 demonstrates that the addition of 1% sucrose reduced freeze-thaw induced aggregation.

[0040] To further examine the ease of freeze-drying, 50 mM phosphate-citrate, 5% mannitol, 1% Prepare a formulation containing sucrose, 0.02% Tween 20, and a final protein concentration of 0.2 mg / ml The pH was 6.5. Samples were lyophilized in glass DP lyo vials and incubated at 50°C, 25°C, and 40°C for 10 min. The samples were then stored at 40°C for one month, two months, and three months. Then, 0.5 ml of ultrapure water was added and the samples were incubated for one hour. Samples were rehydrated by incubation at room temperature and then assessed using several techniques including turbidity, laser light obscuration, SE-UPLC, AE-HLPC, CGE and protein activity. And a significant loss of protein activity was observed at higher temperatures, indicating that this formulation is not suitable for long-term storage. We subsequently found that the ratio of mannitol to sucrose is important for maintaining stability and that trehalose can be interchanged with sucrose to improve long-term stability and maintain liquid stability. Formulations containing mannitol, sucrose, and mannitol esters were evaluated after lyophilization and storage at 25° C. or 40° C. for 4 weeks. Stability was assessed using several techniques including turbidity, laser light obscuration, SE-UPLC, AE-HLPC, and protein activity. The turbidity data is shown in the table below. The data shows that higher concentrations of mannitol compared to sucrose result in increased aggregation.

[0041] [Table 1]

Claims

1. A therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV. Quality; and Surfactants wherein the w / w ratio of surfactant to protein is in the range of 0.75:1 to 1.5:

1.

2. 2. The formulation of claim 1, wherein the w / w ratio of surfactant to protein is 1:

1.

3. 3. The formulation of claim 1 or 2, further comprising a bulking agent.

4. The formulation according to any one of claims 1 to 3, further comprising a stabilizer.

5. The formulation of claim 4 which recites claim 3, wherein the ratio of stabilizer to bulking agent is greater than 1:

1.

6. A therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFV. Q quality; Bulking agents; and Stabilizers wherein the w / w ratio of stabilizer to bulking agent is greater than 1:

1.

7. 7. The formulation of claim 5 or 6, wherein the ratio of stabilizer to bulking agent is greater than 1.5:

1.

8. 8. The formulation of claim 7, wherein the ratio of stabilizer to bulking agent is in the range of 3:1 to 7:

1.

9. The formulation according to any one of claims 6 to 8, further comprising a surfactant.

10. The formulation according to any one of claims 1 to 5 and 9, wherein the surfactant is a polysorbate.

11. The formulation of claim 10, wherein the polysorbate is polysorbate 20.

12. The formulation according to any one of claims 3 to 11, wherein the bulking agent is a polyol.

13. 13. The formulation of claim 12, wherein the polyol is mannitol.

14. The formulation of any one of claims 4 to 13, wherein the stabilizing agent is a disaccharide.

15. The formulation according to any one of claims 1 to 14, further comprising a buffering agent.

16. 16. The formulation of claim 15, wherein the buffer is phosphate / citrate.

17. A formulation according to any one of claims 1 to 16, having a pH in the range of 6 to 7.

18. The formulation according to any one of claims 1 to 17, which is an aqueous solution.

19. The formulation according to any one of claims 1 to 17, which is lyophilized.

20. (i) formulating a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFv; and (ii) a surfactant. wherein the w / w ratio of surfactant to protein is within the range of 0.75:1 to 1.5:

1.

21. (i) formulating a therapeutically effective amount of a bispecific protein comprising a soluble T cell receptor (TCR) and an scFv; (ii) a bulking agent; and (iii) a stabilizing agent. wherein the ratio of stabilizer to bulking agent is greater than 1:

1. method.

22. Method according to claim 20 or 21, modified by the features according to any one of claims 2 to 5 and 7 to 19.

23. A formulation according to any one of claims 1 to 19 for use in medicine.

24. 24. The formulation according to claim 23 for use in a method for treating cancer, preferably melanoma.

Citation Information

Patent Citations

  • Pharmaceutical compositions comprising bispecific antibody constructs for improved storage and administration

    JP2018188437A